8-K: InMed Appoints Takeda Exec John Bathery to Board

InMed Pharmaceuticals strengthens its board with the appointment of John Bathery, a seasoned pharmaceutical executive, while Bryan Baldasare steps down.

Summary

• InMed Pharmaceuticals Inc. appointed Mr. John Bathery to its Board of Directors, effective October 14, 2025.
• The Board size was concurrently increased to six members.
• Mr. Bathery brings over 30 years of pharmaceutical industry experience, including 15+ years in corporate development and strategic partnerships, notably from Takeda Pharmaceuticals.
• Mr. Bryan Baldasare notified the Company on October 15, 2025, that he will not seek re-election at the 2025 Annual General Meeting due to increasing professional obligations.
• There is no disagreement between Mr. Baldasare and the Company regarding his departure.
• Mr. Bathery will receive an annual retainer of US$50,000 for his service as a non-employee director, with potential additional compensation for committee roles.

Sentiment

Score: 7

Explanation: The appointment of a highly experienced director with a strong track record in deal-making and corporate development is a significant positive for the company's strategic direction and potential for future partnerships. The amicable departure of another director is a minor negative, but overshadowed by the new appointment's potential benefits. The mention of 'consistent positive results' for INM-901 by the new director also adds a positive undertone.

Positives

• The appointment of Mr. John Bathery, a highly experienced pharmaceutical executive with over 30 years in the industry and 15+ years in corporate development and strategic partnerships, is a significant strategic enhancement.
• Mr. Bathery's expertise in deal-making, structuring partnerships (including transactions exceeding $60 billion), and global business development is expected to be instrumental as InMed advances its INM-901 and INM-089 programs and explores strategic collaborations.
• Mr. Bathery's comment highlights "consistent positive results seen with INM-901 across multiple parameters," which is encouraging for the Alzheimer's program.
• The departure of Mr. Bryan Baldasare is amicable, with no disagreements reported, ensuring a smooth transition.

Negatives

• The departure of an existing director, Mr. Bryan Baldasare, means the loss of his experience and continuity on the board.

Risks

• Forward-looking statements inherently involve numerous risks, uncertainties, and assumptions, many of which are beyond the company's control.
• Known and unknown risk factors could cause actual results, performance, or achievements to differ materially from forward-looking information.
• A complete discussion of risks and uncertainties is disclosed in InMed's Annual Report on Form 10-K, Item 1, for the period ended June 30, 2025.

Future Outlook

The company anticipates advancing its INM-901 program for Alzheimer's disease and INM-089 program for Age-Related Macular Degeneration toward clinical readiness and actively exploring potential strategic partnerships. Management expects Mr. Bathery's expertise to be instrumental in these efforts and in positioning the company for future growth.

Management Comments

• "We are delighted to welcome John to InMed's Board. His extensive deal-making expertise and proven ability to structure partnerships at the preclinical stage will be instrumental as we advance our development programs and pursue strategic collaborations. John's experience in global business development and corporate development will be a strong asset as we position the Company for future growth." Andrew Hull, Chairman of the Board.
• "I am pleased to join InMed's Board at this pivotal stage in the Company's growth. The consistent positive results seen with INM-901 across multiple parameters are particularly encouraging and highlight the strength of InMed's research. I look forward to supporting the team as we advance InMed's programs and explore strategic opportunities to maximize their potential." Mr. John Bathery.

Industry Context

The appointment of a highly experienced executive with a strong background in pharmaceutical business development and strategic partnerships, particularly from a major player like Takeda, reflects a common industry trend where biotech companies seek to strengthen their boards with expertise crucial for advancing drug candidates through clinical stages and securing value-creating collaborations. This is especially relevant for companies like InMed, which are progressing early-stage assets (INM-901 and INM-089) and looking to monetize their pipeline through partnerships, a key strategy in the capital-intensive pharmaceutical development landscape.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Potential positive impact due to strengthened board expertise, which could lead to more effective strategic partnerships and advancement of drug programs, potentially increasing shareholder value.
• Employees: No direct impact mentioned, but a stronger board could provide better strategic direction for the company's future.
• Customers/Patients: Potential long-term positive impact if the strengthened board leads to successful development and commercialization of drug candidates for diseases like Alzheimer's and AMD.

Next Steps

• Mr. Bathery may be appointed to one or more Board committees (appointments not yet determined).
• Advance INM-901 program for Alzheimer's disease toward clinical readiness.
• Advance INM-089 program in Age-Related Macular Degeneration (AMD) toward clinical readiness.
• Explore potential strategic partnerships for development programs.
• Hold the 2025 Annual General Meeting, where Mr. Baldasare will not stand for re-election and Mr. Bathery's term will expire immediately before it.

Key Dates

Recommendation

The appointment of Mr. John Bathery, a highly experienced executive with a strong track record in corporate development and strategic partnerships, is a positive development that could significantly aid InMed in advancing its pipeline and securing collaborations. This strengthens the company's strategic capabilities. However, this is a governance change, not a direct clinical or financial result. While positive, it doesn't fundamentally alter the immediate investment thesis or provide new financial metrics that would warrant a 'buy' or 'strong buy' without further clinical or financial updates. The amicable departure of Mr. Baldasare is a minor event. Therefore, a 'hold' recommendation is appropriate, acknowledging the positive strategic enhancement while awaiting more substantive operational or financial news.

Keywords

InMed Pharmaceuticals, Board of Directors, John Bathery, Bryan Baldasare, Corporate Governance, Pharmaceutical Industry, Business Development, Strategic Partnerships, Takeda Pharmaceuticals, INM-901, INM-089, Alzheimer's Disease, Age-Related Macular Degeneration, Biotechnology, Drug Development